["{\n\"step_by_step_thinking\": \"The study is designed to assess the antileukemic activity of a new tyrosine kinase inhibitor in patients with chronic myeloid leukemia in blast crisis. The patients are informed that they would be treated with the drug and assigned to successive dose cohorts, not randomized or controlled for comparison purposes. Therefore, it's an open-labeled clinical trial where all patients receive the treatment and their efficacy is determined through regular assessments.\",\n\"answer_choice\": \"C\""]